NEW YORK, NY / ACCESSWIRE / April 22, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.
Inovio Pharmaceuticals, Inc. (NASDAQ:INO)
Investors Affected : February 14, 2020 - March 9, 2020
A class action has commenced on behalf of certain shareholders in Inovio Pharmaceuticals, Inc. According to a filed complaint, throughout the class period, defendants made misleading statements about the company’s development of a purported vaccine for the novel coronavirus, artificially inflating the company’s share price and resulting in significant investor losses.
Shareholders may find more information at https://securitiesclasslaw.com/securities/inovio-pharmaceuticals-inc-loss-submission-form/?id=6127&from=1
XP Inc. (NASDAQ:XP)
Investors Affected : or otherwise acquired XP’s securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with XP’s December 2019 initial public offering.
A class action has commenced on behalf of certain shareholders in XP Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) XP engaged in undisclosed related party transactions; (2) XP failed to disclose its common and large system failures and connected losses; (3) XP’s aggressive IFA strategy was and is tenuous; (4) XP had material weaknesses; (5) XP fired its previous accounting firm due to that firm finding and disclosing material weaknesses; and (6) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
Shareholders may find more information at https://securitiesclasslaw.com/securities/xp-inc-loss-submission-form/?id=6127&from=1
Gossamer Bio, Inc. (NASDAQ:GOSS)
Investors Affected : common stock between February 8, 2019 and December 13, 2019 and/or who acquired Gossamer shares pursuant or traceable to Gossamer’s documents issued in connection with its February 8, 2019 initial public offering.
A class action has commenced on behalf of certain shareholders in Gossamer Bio, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose: (1) the reasons for Gossamer’s GB001 trial failures; (2) the purported clinical validation of Novartis’ oral DP2 antagonist; and (3) that, as a result of the foregoing, Defendants’ public statements were materially false and misleading at all relevant times.
Shareholders may find more information at https://securitiesclasslaw.com/securities/gossamer-bio-inc-loss-submission-form/?id=6127&from=1
The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (212) 537-9430
Fax: (833) 862-7770
SOURCE: The Gross Law Firm